Navigation Links
TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
Date:1/29/2009

SCOTTSDALE, Ariz. Jan. 29, 2008 TGen Clinical Research Services (TCRS) at Scottsdale Healthcare and Mayo Clinic are testing a new drug that may offer broad potential to treat solid tumors.

Clinical trials of the drug TH-302 are being conducted at TGen Clinical Research Services at Scottsdale Healthcare, a partnership of the Phoenix-based Translational Genomics Research Institute (TGen) and Scottsdale-based Scottsdale Healthcare Corp., and at Mayo Clinic in Arizona.

Dr. Glen Weiss, Director of Thoracic Oncology at TCRS at Scottsdale Healthcare, said the new drug appears promising and may be more effective and less toxic to healthy tissues than conventional drugs.

"TH-302 is a new, novel, small molecule that is activated under a metabolic condition characteristic of cancer cells hypoxia (lack of oxygen). The drug candidate may provide an opportunity to treat slowly dividing tumor cells within hypoxic regions that generally evade traditional chemotherapeutic agents and ultimately contribute to relapse," Dr. Weiss said.

Phase 1 and Phase 1/2 trials are underway to investigate the safety and activity of TH-302 in patients with advanced solid tumors. After evidence of tumor activity was observed in the Phase 1 trial in patients with advanced melanoma both non-small cell lung cancer and small cell lung cancer the study was expanded to further investigate TH-302 anti-tumor activity in these tumors. Both Phase 1 and 1/2 trials continue to enroll patients with other solid tumors. If successful, Phase 2 and 3 clinical trials will confirm the drug's effectiveness on solid tumors.

In cancer, as a tumor grows, it rapidly outgrows its blood supply, leaving portions of the tumor with regions where the oxygen concentration is significantly lower than in healthy tissues. This condition is called tumor hypoxia. Several studies have shown that higher levels of tumor hypoxia correlate with poor treatment outcomes for a variety of solid tumors. It is believed that hypoxia may severely limit the curability of tumors.

TH-302 is converted selectively in the presence of hypoxia to the drug's active form, bromo-isophosphoramide mustard, a potent DNA alkylator. TH-302 targets levels of hypoxia that are common in tumors but are rare in normal tissues this is how selective targeting of the tumor occurs. After conversion to the active form of the drug, the more resistant hypoxic cells are exposed to high concentrations of released cytotoxic agent, which can also diffuse into the oxygenated regions of a tumor cell.

The Phase 1/2 trials are investigating the safety and activity of TH-302 in combination with a number of conventional chemotherapies that are believed to be effective in the non-hypoxic regions of solid tumors.


'/>"/>

Contact: Steve Yozwiak
syozwiak@tgen.org
602-343-8704
The Translational Genomics Research Institute
Source:Eurekalert

Related biology news :

1. 3 new informatics pilot projects to aid clinical and translational scientists nationwide
2. Genome Medicine: Bridging the gap between research and clinical practice
3. Far-reaching genetics topics to be addressed: 2009 Annual Clinical Genetics Meeting, March 25-29
4. In just 5 years, gene discovery to clinical trial of potential treatment
5. New book helps medical students master clinical skills
6. Biochemistry of human physiology in health and disease is focus of updated clinical text
7. Self-assembling nano-fiber gel delivers high concentrations of clinically approved drugs
8. A new journal where molecular biology meets clinical research
9. Prosthetic vein valve designed to direct blood flow shows promising pre-clinical results
10. Clinical trial for new tuberculosis vaccine
11. JDRF-funded clinical trial demonstrates continuous glucose monitoring improves blood sugar control
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/18/2016)... 2016 --> --> ... Manned & Unmanned Vehicles, Physical infrastructure and Perimeter Surveillance & ... the border security market and the continuing migration crisis in ... Europe has led visiongain to publish this unique ... --> defence & security companies in the border ...
(Date:3/15/2016)... Yissum Research Development Company of the Hebrew University ... University, announced today the formation of Neteera Technologies ... biological indicators. Neteera Technologies has completed its first round ... Neteera,s ... from sweat ducts, enables reliable and speedy biometric identification, ...
(Date:3/11/2016)... http://www.apimages.com ) - --> http://www.apimages.com ) - ... Images ( http://www.apimages.com ) - Germany . ... new refugee identity cards. DERMALOG will be unveiling this device, and ... Hanover next week.   --> Germany ... the new refugee identity cards. DERMALOG will be unveiling this device, ...
Breaking Biology News(10 mins):
(Date:5/3/2016)... - And Other Rising Companies ... Those Competitor Biologics  - Biosimilar Drug Producers ... ,  Who are the most important and ... their sales potentials? Discover, in our updated survey, organisations, ... and revenue forecasting. Visiongain,s new ...
(Date:5/2/2016)... YORK , May 2, 2016 ... announces that its technology partner Mannin Research Inc. will ... Ophthalmology (ARVO), which takes place from May 1-5, 2016 ... executives will be meeting with its vendors and research ... explore business development goals and other collaborative opportunities for ...
(Date:4/29/2016)... (PRWEB) , ... April 30, 2016 , ... The MIT ... textile design, the bioLogic team explored how bacterial properties can be applied to fabric ... using Natto bacteria, which move in response to humidity change. The team harvested Natto ...
(Date:4/29/2016)... Denver, CO (PRWEB) , ... April 29, 2016 ... ... on addressing the necessary fundamentals to transform technology into a viable company, CereScan’s ... enable growth. Mr. Kelley, a recognized leader and mentor in the Denver ...
Breaking Biology Technology: